BR0015938A - Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa - Google Patents

Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa

Info

Publication number
BR0015938A
BR0015938A BR0015938-7A BR0015938A BR0015938A BR 0015938 A BR0015938 A BR 0015938A BR 0015938 A BR0015938 A BR 0015938A BR 0015938 A BR0015938 A BR 0015938A
Authority
BR
Brazil
Prior art keywords
disorders
beta
drug
manufacture
treatment
Prior art date
Application number
BR0015938-7A
Other languages
English (en)
Inventor
Robert J Collier Jr
Michael A Kapin
Louis Desantis Jr
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0015938A publication Critical patent/BR0015938A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE ANTAGONISTAS BETA-ADRENOCEPTORES PARA A FABRICAçãO DE UM MEDICAMENTO PARA O TRATAMENTO DE DESORDENS DA RETINA EXTERNA". A invenção refere-se ao uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa.
BR0015938-7A 1999-11-30 2000-11-29 Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa BR0015938A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16799399P 1999-11-30 1999-11-30
PCT/US2000/032575 WO2001043737A1 (en) 1999-11-30 2000-11-29 Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

Publications (1)

Publication Number Publication Date
BR0015938A true BR0015938A (pt) 2002-08-27

Family

ID=22609644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015938-7A BR0015938A (pt) 1999-11-30 2000-11-29 Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa

Country Status (18)

Country Link
US (4) US7081482B2 (pt)
EP (1) EP1244438B1 (pt)
JP (2) JP4758581B2 (pt)
CN (1) CN1245966C (pt)
AT (1) ATE253905T1 (pt)
AU (1) AU782524B2 (pt)
BR (1) BR0015938A (pt)
CA (1) CA2388728C (pt)
DE (1) DE60006584T2 (pt)
DK (1) DK1244438T3 (pt)
ES (1) ES2210023T3 (pt)
HK (1) HK1047695B (pt)
MX (1) MXPA02005378A (pt)
PL (1) PL214875B1 (pt)
PT (1) PT1244438E (pt)
TR (1) TR200302008T4 (pt)
WO (1) WO2001043737A1 (pt)
ZA (1) ZA200203133B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245966C (zh) * 1999-11-30 2006-03-22 爱尔康公司 β－肾上腺素受体拮抗剂用于制备治疗外层视网膜疾病的药物的用途
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
CA2717825A1 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd. Opthalmic composition
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
CN110769855A (zh) * 2017-04-21 2020-02-07 史蒂文·霍夫曼 用于治疗视网膜病变的组合物和方法
WO2019213358A1 (en) * 2018-05-03 2019-11-07 Alimera Sciences, Inc. Methods of treating retinal diseases
JP7392219B2 (ja) * 2020-01-20 2023-12-06 株式会社萌芽プランツ フラボノイド組成物
US20230248671A1 (en) * 2020-07-10 2023-08-10 Chang Gung Memorial Hospital, Linkou Use of beta-1 adrenergic receptor antagonist for preparing compositions for reducing epithelial cell damage induced by epidermal growth factor receptor inhibitors and inhibiting cancer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4443432A (en) 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
US6486208B1 (en) * 1998-09-25 2002-11-26 Alcon Laboratories, Inc. Sustained release, and comfortable opthalmic composition and method for ocular therapy
CN1245966C (zh) 1999-11-30 2006-03-22 爱尔康公司 β－肾上腺素受体拮抗剂用于制备治疗外层视网膜疾病的药物的用途

Also Published As

Publication number Publication date
PT1244438E (pt) 2004-02-27
US7081482B2 (en) 2006-07-25
MXPA02005378A (es) 2005-02-25
ES2210023T3 (es) 2004-07-01
EP1244438B1 (en) 2003-11-12
CN1245966C (zh) 2006-03-22
CN1402634A (zh) 2003-03-12
US8710102B2 (en) 2014-04-29
CA2388728C (en) 2009-05-19
PL214875B1 (pl) 2013-09-30
TR200302008T4 (tr) 2004-01-21
AU2052701A (en) 2001-06-25
ATE253905T1 (de) 2003-11-15
EP1244438A1 (en) 2002-10-02
HK1047695B (en) 2004-08-20
US20080103211A1 (en) 2008-05-01
US20060199868A1 (en) 2006-09-07
JP4758581B2 (ja) 2011-08-31
US20020193373A1 (en) 2002-12-19
US20100249134A1 (en) 2010-09-30
ZA200203133B (en) 2003-04-22
DE60006584D1 (de) 2003-12-18
JP2010215667A (ja) 2010-09-30
WO2001043737A1 (en) 2001-06-21
CA2388728A1 (en) 2001-06-21
DK1244438T3 (da) 2004-02-23
HK1047695A1 (en) 2003-03-07
PL356001A1 (en) 2004-05-31
JP2003516963A (ja) 2003-05-20
AU782524B2 (en) 2005-08-04
DE60006584T2 (de) 2004-09-30

Similar Documents

Publication Publication Date Title
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
PT2336184E (pt) Administração de agentes para o tratamento da inflamação
PT1147083E (pt) Derivados de arilpiperazinil-ciclohexilindole para o tratamento da depressao
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
HRP20080467A2 (hr) Derivati 5-beta-sapogenina i pseudosapogenina te njihova uporaba u liječenju demencije
PT1263504E (pt) Compostos com actividade 5-ht1a uteis para o tratamento de perturbacoes da retina externa
PT1235571E (pt) Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino
BR9710693A (pt) Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
EE04903B1 (et) Taksoidi derivaatide kasutamine ravimi valmistamiseks, mis on ette n„htud rakkude ebaloomuliku proliferatsiooni raviks imetajate ajus
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
PT1150704E (pt) Melagatran para o tratamento da inflamacao
WO2000064423A3 (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression
GB9923078D0 (en) Sapogenin derivatives and their use
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
PT1148874E (pt) Uso de derivados anticonvulsivos para o tratamento da bulimia nervosa
EE200200670A (et) S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
NO20042586L (no) Behandlingsfremgangsmate
BR0206918A (pt) Uso de iloperidona

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 ( VII ) DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]